Bristol Myers Gets FDA OK of Breyanzi in Follicular Lymphoma

By Colin Kellaher


Bristol Myers Squibb has won U.S. Food and Drug Administration expanded approval of its CAR-T cell therapy Breyanzi for adults with relapsed or refractory follicular lymphoma...

Related Keywords

Colin Kellaher , Bristol Myers Squibb , Drug Administration , Myers Squibb , Dow Jones ,